Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment
MA Gertz - American journal of hematology, 2020 - Wiley Online Library
Abstract Disease Overview Immunoglobulin light chain amyloidosis is a clonal,
nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy …
nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy …
Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis
I Vaxman, M Gertz - Acta Haematologica, 2019 - karger.com
The term amyloidosis refers to a group of disorders in which protein fibrils accumulate in
certain organs, disrupt their tissue architecture, and impair the function of the effected organ …
certain organs, disrupt their tissue architecture, and impair the function of the effected organ …
Prognosis and staging of AL amyloidosis
T Dittrich, C Kimmich, U Hegenbart… - Acta haematologica, 2020 - karger.com
The treatment options for systemic light chain amyloidosis (AL) are currently widening in an
unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as …
unprecedented way, brought about by an expanding arsenal of anti-myeloma therapy as …
Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment
MA Gertz - American journal of hematology, 2018 - Wiley Online Library
Abstract Disease Overview Immunoglobulin light chain amyloidosis is a clonal,
nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy …
nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy …
Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?
Aim: Digoxin is considered contraindicated in light-chain (AL) amyloidosis, given reports of
increased toxicity published 30–50 years ago. We sought to determine the frequency of …
increased toxicity published 30–50 years ago. We sought to determine the frequency of …
New developments in diagnosis, risk assessment and management in systemic amyloidosis
Amyloidosis is a group of disorders characterized by a misfolded protein that deposits in
organs and compromise their function. Clinician should have a high index of suspicion …
organs and compromise their function. Clinician should have a high index of suspicion …
Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern
Improvement in survival in Light chain (AL) amyloidosis has been seen over recent decades,
enabling more patients to achieve long‐term survival. Patients with AL amyloidosis who …
enabling more patients to achieve long‐term survival. Patients with AL amyloidosis who …
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
We explored the association between bone marrow plasma cells (BMPCs) and disease
presentation and outcome among 1574 AL patients. Three BMPC groups were formulated:< …
presentation and outcome among 1574 AL patients. Three BMPC groups were formulated:< …
Biomarkers in AL amyloidosis
Systemic AL amyloidosis is a rare complex hematological disorder caused by clonal plasma
cells which produce amyloidogenic immunoglobulins. Outcome and prognosis is the …
cells which produce amyloidogenic immunoglobulins. Outcome and prognosis is the …
Clinical considerations for immunoparesis in multiple myeloma
M Chahin, Z Branham, A Fox, C Leurinda… - Cancers, 2022 - mdpi.com
Simple Summary Immunoparesis in multiple myeloma is defined as the suppression of one
or more of the uninvolved immunoglobulins, AKA, polyclonal immunoglobulin. The extent of …
or more of the uninvolved immunoglobulins, AKA, polyclonal immunoglobulin. The extent of …